Pharmacovigilance is the science relating to the detection, assessment, understanding and prevention of adverse effects and other problems related to medicines. Part of the pharmacovigilance process occurs after the product has been made available for public consumption to detect safety issues in diverse and vulnerable populations. The spontaneous reporting system of adverse events has been adopted worldwide and is dependent on healthcare professionals.

The treatment of drug-resistant tuberculosis (DR-TB) is often influenced by adverse drug reactions and can impact patient outcomes. Thus, the WHO recommends targeted spontaneous reporting for special populations, such as those living with DR-TB, who are specifically monitored for adverse events. While the incidence of adverse events associated with DR-TB medication are well documented, the reporting to regulatory bodies is lacking. The primary aim of the study was to understand the current adverse event reporting practices in specialised DR-TB treatment facilities in South Africa.

Chair:
Prof Priscilla Reddy, Health and Wellbeing, Human and Social Capabilities, HSRC

Presenters:
Dr Razia Gaida & Mr Adlai Davids, Human and Social Capabilities , HSRC